A CRA expert led risk management due diligence efforts for two separate $1 billion motion-picture-backed resecuritization financing facilities. Our expert identified risk related to the likelihood of default, and it was considered by reinsurers in their decision to underwrite the respective facilities.
Biosimilars: Economic Issues for IP Litigation
In July 2021, the U.S. Food and Drug Administration granted a determination of interchangeability to a biosimilar drug for the first time. This approval has...